Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy
Primary Purpose
Vaginosis, Bacterial, Premature Birth, Birth Weight
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
oral versus vaginal metronidazole
Sponsored by
About this trial
This is an interventional treatment trial for Vaginosis, Bacterial focused on measuring Bacterial Vaginosis, Metronidazole
Eligibility Criteria
Inclusion Criteria: African American, Hispanic, Asian/Pacific Islander, Native American, and white women. - Exclusion Criteria: Women with a prior preterm delivery, multiple gestation, chronic hypertension or pre-existing diabetes, antibiotic use before enrollment in the study, allergy to metronidazole, history of alcohol abuse in past year, and women under age 18. -
Sites / Locations
- University of Washington
Outcomes
Primary Outcome Measures
changes in vaginal flora
Secondary Outcome Measures
preterm delivery
low birth weight
chorioamnionitis
Full Information
NCT ID
NCT00153517
First Posted
September 8, 2005
Last Updated
September 8, 2005
Sponsor
Centers for Disease Control and Prevention
1. Study Identification
Unique Protocol Identification Number
NCT00153517
Brief Title
Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy
Official Title
Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy (Randomized Trial of BV Treatment in Pregnancy)
Study Type
Interventional
2. Study Status
Record Verification Date
September 2005
Overall Recruitment Status
Completed
Study Start Date
October 1999 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
March 2005 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Centers for Disease Control and Prevention
4. Oversight
5. Study Description
Brief Summary
The goal of this study is to examine acceptability and efficacy of 2 kinds of BV treatment among women at low risk for preterm delivery. The objectives are:
To examine the side effects and patient acceptability of oral versus intravaginal metronidazole.
To compare the efficacy of oral and intravaginal metronidazole for the treatment of BV
To study the efficacy of oral and intravaginal metronidazole for the prevention of hospital admission during the 3rd trimester, chorioamnionitis, preterm delivery, and maternal infectious morbidity.
Detailed Description
This is a randomized, placebo-controlled intervention trial. Women diagnosed as BV+ by Gram stain at 12-16 weeks gestation are randomly assigned to the following treatment groups: oral metronidazole (250 mg TID x 7 days) with intravaginal placebo; intravaginal metronidazole (5g 0.75% gel BID x 5 days) with oral placebo. African American, Hispanic, Asian/Pacific Islander, Native American, and white women are eligible. Women with a prior preterm delivery, multiple gestation, chronic hypertension or pre-existing diabetes, antibiotic use before enrollment in the study, allergy to metronidazole, history of alcohol abuse in past year, and women under age 18 are excluded.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vaginosis, Bacterial, Premature Birth, Birth Weight, Chorioamnionitis
Keywords
Bacterial Vaginosis, Metronidazole
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
Double
Allocation
Randomized
Enrollment
126 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
oral versus vaginal metronidazole
Primary Outcome Measure Information:
Title
changes in vaginal flora
Secondary Outcome Measure Information:
Title
preterm delivery
Title
low birth weight
Title
chorioamnionitis
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: African American, Hispanic, Asian/Pacific Islander, Native American, and white women.
-
Exclusion Criteria: Women with a prior preterm delivery, multiple gestation, chronic hypertension or pre-existing diabetes, antibiotic use before enrollment in the study, allergy to metronidazole, history of alcohol abuse in past year, and women under age 18.
-
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jane E Hitti, MD, MPH
Organizational Affiliation
University of Washington
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Washington
City
Seattle
State/Province
Washington
ZIP/Postal Code
98185
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
19515236
Citation
Mitchell CM, Hitti JE, Agnew KJ, Fredricks DN. Comparison of oral and vaginal metronidazole for treatment of bacterial vaginosis in pregnancy: impact on fastidious bacteria. BMC Infect Dis. 2009 Jun 10;9:89. doi: 10.1186/1471-2334-9-89.
Results Reference
derived
Learn more about this trial
Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy
We'll reach out to this number within 24 hrs